Go Pro
→ DOJ Admits It In Court—Your Cash Can Be Seized Without Warning (From Priority Gold) (Ad)tc pixel Free NNVC Stock Alerts

NanoViricides (NNVC) Financials

NanoViricides logo
$1.75 -0.02 (-1.13%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for NanoViricides

Annual Income Statements for NanoViricides

This table shows NanoViricides' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.20 -11 -10 -8.56 -8.42 -27 -8.82 -8.11 -8.59 -8.29 -9.47
Consolidated Net Income / (Loss)		 -2.20 -11 -10 -8.56 -8.42 -13 -8.82 -8.11 -8.59 -8.29 -9.47
Net Income / (Loss) Continuing Operations		 -2.20 -11 -10 -8.56 -8.42 -27 -8.82 -8.11 -8.59 -8.24 -9.47
Total Pre-Tax Income 		-2.20 -11 -10 -8.56 -8.42 -13 -8.82 0.00 -8.59 -8.24 -9.47
Total Operating Income		 -7.06 -8.86 -9.60 -9.33 -8.66 -16 -8.74 -8.11 -8.94 -8.52 -9.59
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 7.06 8.86 9.60 9.33 8.66 16 8.74 8.11 8.94 8.52 9.59
Selling, General & Admin Expense		 3.40 3.83 3.03 3.41 2.74 3.30 2.63 2.33 2.55 3.08 4.04
Research & Development Expense		 3.66 5.03 6.57 5.91 5.92 4.70 6.11 5.78 6.39 5.44 5.55
Total Other Income / (Expense), net		 4.86 -1.87 -0.70 0.76 0.24 -11 -0.08 0.01 0.35 0.22 0.12
Other Income / (Expense), net		 7.51 -0.82 0.41 2.30 0.24 -11 0.01 0.01 0.36 0.27 0.12
Basic Earnings per Share		 ($0.04) ($0.19) ($0.17) ($2.64) ($2.35) ($2.39) ($0.81) ($0.70) ($0.74) ($0.70) ($0.63)
Weighted Average Basic Shares Outstanding		 56.55M 57.67M 60.10M 3.25M 3.59M 5.62M 10.90M 11.53M 11.63M 11.87M 15.12M
Diluted Earnings per Share		 ($0.09) ($0.19) ($0.17) ($2.64) ($2.35) ($2.39) ($0.81) ($0.70) ($0.74) ($0.70) ($0.63)
Weighted Average Diluted Shares Outstanding		 59.22M 57.67M 60.10M 3.25M 3.59M 5.62M 10.90M 11.53M 11.63M 11.87M 15.12M
Weighted Average Basic & Diluted Shares Outstanding		 55M 56.40M 60.10M 3.25M 3.59M 5.62M 10.90M - - 14.68M 17.43M

Quarterly Income Statements for NanoViricides

This table shows NanoViricides' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.97 -2.11 -1.85 -2.36 -3.13 -2.03 -2.22 -2.10 -1.79 -2.22 -1.99
Consolidated Net Income / (Loss)		 -1.97 -2.11 -1.85 -2.36 -3.13 -2.03 -2.22 -2.10 -1.79 -2.22 -1.99
Net Income / (Loss) Continuing Operations		 -1.97 -2.10 -1.85 -2.32 -3.13 -2.03 -2.22 -2.10 -1.79 -2.22 -1.99
Total Pre-Tax Income 		0.00 -2.10 -1.85 -4.29 -3.13 -2.03 -2.22 -5.22 -1.79 -2.22 -1.99
Total Operating Income		 -2.03 -2.18 -1.91 -2.39 -3.17 -2.06 -2.25 -2.12 -1.80 -2.23 -2.03
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 2.03 2.18 1.91 2.39 3.17 2.06 2.25 2.12 1.80 2.23 2.03
Selling, General & Admin Expense		 0.56 0.61 0.69 1.21 1.23 0.90 0.97 0.94 0.80 1.11 0.74
Research & Development Expense		 1.47 1.57 1.21 1.18 1.93 1.16 1.28 1.18 0.99 1.12 1.29
Total Other Income / (Expense), net		 0.06 0.07 0.05 0.04 0.04 0.03 0.03 0.02 0.01 0.01 0.04
Interest Expense		 0.04 - - - - - 0.00 - - - 0.00
Other Income / (Expense), net		 0.10 0.08 0.05 0.04 0.04 0.03 0.03 0.02 0.01 0.01 0.04
Basic Earnings per Share		 ($0.17) ($0.18) ($0.16) ($0.19) ($0.23) ($0.14) ($0.14) ($0.12) ($0.10) ($0.11) ($0.09)
Weighted Average Basic Shares Outstanding		 11.72M 11.75M 11.78M 11.87M 13.72M 14.57M 16.03M 15.12M 17.08M 19.85M 21.61M
Diluted Earnings per Share		 ($0.17) ($0.18) ($0.16) ($0.19) ($0.23) ($0.14) ($0.14) ($0.12) ($0.10) ($0.11) ($0.09)
Weighted Average Diluted Shares Outstanding		 11.72M 11.75M 11.78M 11.87M 13.72M 14.57M 16.03M 15.12M 17.08M 19.85M 21.61M
Weighted Average Basic & Diluted Shares Outstanding		 11.75M 11.78M 11.81M 14.68M 14.35M 15.64M 16.07M 17.43M 18.00M 21.60M 21.65M

Annual Cash Flow Statements for NanoViricides

This table details how cash moves in and out of NanoViricides' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -5.23 -7.31 -8.06 -8.02 -4.53 11 6.81 -6.45 -5.92 -3.35 -3.24
Net Cash From Operating Activities		 -6.21 -6.83 -7.90 -7.78 -6.80 -6.67 -8.21 -5.89 -5.67 -6.32 -8.48
Net Cash From Continuing Operating Activities		 -6.21 -6.83 -7.90 -7.78 -6.80 -6.67 -8.21 -5.89 -5.67 -6.32 -8.48
Net Income / (Loss) Continuing Operations		 -2.20 -11 -10 -8.56 -8.42 -13 -8.82 -8.11 -8.59 -8.29 -9.47
Consolidated Net Income / (Loss)		 -2.20 -11 -10 -8.56 -8.42 -13 -8.82 -8.11 -8.59 -8.29 -9.47
Depreciation Expense		 0.29 0.65 0.65 0.67 0.69 0.69 0.70 0.72 0.74 0.75 0.74
Amortization Expense		 1.18 1.44 1.36 0.37 0.01 0.03 0.03 0.01 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 2.87 2.01 2.58 -0.55 0.54 1.32 0.43 1.28 0.37 0.22 0.22
Changes in Operating Assets and Liabilities, net		 -8.36 -0.20 -2.18 2.59 0.85 -5.74 -0.54 0.21 1.80 1.00 0.02
Net Cash From Investing Activities		 -5.76 0.00 0.00 -0.24 -0.07 -0.01 -0.24 -0.32 -0.15 -0.16 -0.06
Net Cash From Continuing Investing Activities		 -5.76 0.00 0.00 -0.24 -0.07 -0.01 -0.24 -0.32 -0.15 -0.16 -0.06
Purchase of Property, Plant & Equipment		 -6.76 - - - - - -0.24 -0.32 -0.15 -0.16 -0.06
Net Cash From Financing Activities		 6.74 0.00 0.00 0.00 2.35 18 15 -0.23 -0.09 3.12 5.30
Net Cash From Continuing Financing Activities		 6.74 0.00 0.00 0.00 2.35 18 15 -0.23 -0.09 3.12 5.30
Issuance of Common Equity		 - - 0.00 0.00 2.35 17 17 - 0.00 3.12 5.30
Cash Interest Paid		 0.98 1.04 0.17 0.17 0.00 0.00 0.00 0.01 0.00 0.05 0.00

Quarterly Cash Flow Statements for NanoViricides

This table details how cash moves in and out of NanoViricides' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.18 -1.72 -1.99 1.54 -0.93 0.09 -1.42 -0.98 -0.43 4.02 -1.94
Net Cash From Operating Activities		 -1.17 -1.72 -1.94 -1.48 -2.59 -2.19 -1.99 -1.70 -1.59 -2.05 -1.93
Net Cash From Continuing Operating Activities		 -1.17 -1.72 -1.94 -1.48 -2.59 -2.19 -1.99 -1.73 -1.59 -2.05 -1.93
Net Income / (Loss) Continuing Operations		 -1.97 -2.11 -1.85 -2.36 -3.13 -2.03 -2.22 -2.10 -1.79 -2.22 -1.99
Consolidated Net Income / (Loss)		 -1.97 -2.11 -1.85 -2.36 -3.13 -2.03 -2.22 -2.10 -1.79 -2.22 -1.99
Depreciation Expense		 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.16 0.13 0.13 0.13
Amortization Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.07 0.05 0.05 0.05 0.06 0.05 0.06 0.05 0.05 0.20 0.07
Changes in Operating Assets and Liabilities, net		 0.54 0.16 -0.33 0.64 0.28 -0.41 -0.02 0.16 0.01 -0.16 -0.14
Net Cash From Financing Activities		 0.00 - - 3.12 1.71 2.28 0.58 0.73 1.25 6.07 -0.01
Net Cash From Continuing Financing Activities		 0.00 - - 3.12 1.71 2.28 0.58 0.73 1.25 6.07 -0.01
Issuance of Common Equity		 0.00 - - 3.12 1.71 2.28 0.58 0.73 1.25 6.07 -0.01

Annual Balance Sheets for NanoViricides

This table presents NanoViricides' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 44 37 27 19 13 24 30 23 17 13 8.82
Total Current Assets		 32 24 15 7.32 2.83 14 21 14 8.45 4.97 1.67
Cash & Equivalents		 31 24 15 7.08 2.56 14 21 14 8.15 4.80 1.56
Prepaid Expenses		 0.21 0.22 0.19 0.24 0.27 0.28 0.31 0.35 0.30 0.17 0.11
Plant, Property, & Equipment, net		 12 12 11 11 10 9.54 9.08 8.69 8.11 7.51 6.83
Total Noncurrent Assets		 0.54 0.49 0.44 0.38 0.40 0.38 0.35 0.38 0.35 0.34 0.32
Intangible Assets		 0.40 0.39 0.38 0.37 0.37 0.36 0.35 0.34 0.33 0.33 0.32
Other Noncurrent Operating Assets		 0.14 0.10 0.06 0.01 0.03 0.03 0.00 0.04 0.01 0.01 0.00
Total Liabilities & Shareholders' Equity		 44 37 27 19 13 24 30 23 17 13 8.82
Total Liabilities		 12 14 6.68 0.88 2.85 2.16 0.35 0.41 2.03 1.36 1.31
Total Current Liabilities		 0.60 6.74 4.67 0.88 2.85 2.16 0.35 0.41 0.53 1.36 1.31
Accounts Payable		 0.41 0.86 0.48 0.33 1.13 0.94 0.23 0.27 0.39 1.10 1.28
Accrued Expenses		 0.03 0.04 0.03 0.25 0.07 0.07 0.02 0.05 0.14 0.26 0.03
Total Noncurrent Liabilities		 12 6.84 2.02 0.00 0.00 0.00 0.00 0.00 1.50 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 32 23 20 18 11 22 30 23 15 11 7.52
Total Preferred & Common Equity		 32 23 20 18 11 22 30 23 15 11 7.52
Preferred Stock		 - 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 32 23 20 18 11 22 30 23 15 11 7.52
Common Stock		 86 88 95 101 103 127 144 146 146 151 156
Retained Earnings		 -54 -65 -75 -84 -92 -106 -114 -122 -131 -139 -149

Quarterly Balance Sheets for NanoViricides

This table presents NanoViricides' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 15 13 11 12 12 10 8.36 12 10
Total Current Assets		 7.14 5.32 3.52 4.04 4.07 2.73 1.25 5.30 3.38
Cash & Equivalents		 6.97 5.25 3.26 3.87 3.96 2.54 1.13 5.15 3.21
Prepaid Expenses		 0.17 0.07 0.26 0.18 0.11 0.18 0.13 0.15 0.16
Plant, Property, & Equipment, net		 7.93 7.75 7.60 7.37 7.17 6.98 6.79 6.66 6.53
Total Noncurrent Assets		 0.35 0.34 0.35 0.33 0.33 0.32 0.32 0.31 0.31
Intangible Assets		 0.33 0.33 0.33 0.32 0.32 0.32 0.31 0.31 0.31
Other Noncurrent Operating Assets		 0.01 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 15 13 11 12 12 10 8.36 12 10
Total Liabilities		 2.45 0.95 0.81 1.63 1.18 1.20 1.18 1.20 1.07
Total Current Liabilities		 0.95 0.95 0.81 1.63 1.18 1.20 1.18 1.20 1.07
Accounts Payable		 0.61 0.77 0.55 1.35 1.12 1.17 1.16 1.15 1.04
Accrued Expenses		 0.34 0.18 0.26 0.28 0.07 0.03 0.03 0.05 0.03
Total Noncurrent Liabilities		 1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13 12 11 10 10 8.83 7.17 11 9.15
Total Preferred & Common Equity		 13 12 11 10 10 8.83 7.17 11 9.15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 13 12 11 10 10 8.83 7.17 11 9.15
Common Stock		 146 148 148 153 155 156 158 164 164
Retained Earnings		 -133 -135 -137 -143 -145 -147 -151 -153 -155

Annual Metrics And Ratios for NanoViricides

This table displays calculated financial ratios and metrics derived from NanoViricides' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 57,150,000.00 57,973,000.00 63,072,000.00 68,985,000.00 76,735,000.00 9,073,000.00 11,505,000.00 11,554,000.00 11,666,000.00 11,814,000.00 16,072,000.00
DEI Adjusted Shares Outstanding		 2,857,500.00 2,898,650.00 3,153,600.00 3,449,250.00 3,836,750.00 9,073,000.00 11,505,000.00 11,554,000.00 11,666,000.00 11,814,000.00 16,072,000.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.77 -3.70 -3.27 -2.48 -2.20 -2.95 -0.77 -0.70 -0.74 -0.70 -0.59
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 119.84% -493.65% 5.46% 16.57% -29.01% -235.81% 69.13% 7.91% -6.26% 4.53% -16.53%
EBIT Growth		 104.30% -2,244.82% 5.07% 23.51% -19.84% -216.62% 67.25% 7.25% -6.00% 4.00% -14.83%
NOPAT Growth		 18.51% -25.43% -8.37% 2.87% 7.14% -84.68% 45.33% 7.21% -10.23% 4.78% -12.63%
Net Income Growth		 83.84% -387.89% 3.92% 16.90% 1.62% -59.61% 34.39% 8.11% -5.94% 3.43% -14.14%
EPS Growth		 66.67% -111.11% 10.53% 16.90% 1.62% -1.70% 66.11% 13.58% -5.71% 5.41% 10.00%
Operating Cash Flow Growth		 1.92% -9.93% -15.65% 1.54% 12.51% 2.02% -23.23% 28.28% 3.75% -11.38% -34.25%
Free Cash Flow Firm Growth		 111.29% -562.20% -12.63% 32.70% 54.61% -217.76% 33.33% 29.00% 25.28% -49.26% -1.61%
Invested Capital Growth		 -93.66% 833.90% 106.42% 13.24% -23.98% 0.05% 16.71% -4.03% -25.51% -0.74% -10.61%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 147.47% -9.68% -19.23% 8.18% -7.80% -89.02% 49.37% 0.00% 0.00% 13.97% 2.58%
EBIT Q/Q Growth		 107.91% -8.49% -12.26% 9.67% -7.13% -84.71% 47.25% 0.00% 0.00% 12.84% 2.67%
NOPAT Q/Q Growth		 14.98% 0.60% 2.53% -0.38% 1.30% -85.63% 47.19% 0.00% 0.00% 13.11% 2.79%
Net Income Q/Q Growth		 73.46% -7.34% -9.65% 9.58% -7.14% 7.48% -7.91% 0.00% 0.00% 12.77% 2.67%
EPS Q/Q Growth		 40.00% -11.76% -13.33% 9.58% -7.14% -7.17% 58.67% 0.00% 0.00% 13.58% 10.00%
Operating Cash Flow Q/Q Growth		 -5.08% -1.89% 4.51% -47.67% 21.36% -0.55% -6.75% 12.35% -1.81% 0.27% -2.67%
Free Cash Flow Firm Q/Q Growth		 115.08% -64.07% -566.65% 10.29% 42.17% -83.41% 37.91% 0.00% 0.00% 0.00% -3.51%
Invested Capital Q/Q Growth		 -95.80% -60.77% 46.58% 24.09% -5.13% -5.92% 4.50% 0.00% 0.00% -9.85% -5.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.60% 100.00%
Interest Burden Percent		 -486.95% 110.77% 112.11% 121.81% 100.00% 50.41% 101.00% 0.00% 100.01% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -7.97% -39.12% -47.52% -45.09% -59.61% -83.11% -34.15% -30.60% -45.27% -63.00% -99.75%
Cash Return on Invested Capital (CROIC)		 54.52% -408.77% -166.35% -77.93% -37.84% -139.17% -85.60% -57.58% -50.35% -88.35% -95.16%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -7.97% -39.11% -47.51% -45.08% -59.60% -83.11% -34.15% -30.60% -45.27% -63.00% -99.75%
Return on Equity Simple (ROE_SIMPLE)		 -6.92% -46.53% -50.71% -48.48% -79.47% -61.80% -29.49% -35.12% -57.77% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.94 -6.20 -6.72 -6.53 -6.06 -11 -6.12 -5.68 -6.26 -5.96 -6.71
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 11.68% -18.16% -24.30% -22.55% -49.03% -27.69% -15.79% -14.04% -20.96% -36.04% -86.62%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -52.00% -89.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 0.45 -9.68 -9.19 -7.03 -8.42 -27 -8.73 -8.10 -8.59 -8.24 -9.47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.93 -7.60 -7.18 -5.99 -7.73 -26 -8.01 -7.38 -7.84 -7.49 -8.72
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.11 4.03 4.19 1.72 1.74 3.12 1.78 0.94 0.90 1.77 2.99
Price to Tangible Book Value (P/TBV)		 3.15 4.09 4.27 1.76 1.80 3.17 1.81 0.96 0.92 1.82 3.12
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 139.03 16.36 7.92 2.20 1.97 6.73 3.50 0.85 0.78 2.33 3.51
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 34.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 149.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 30.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.24 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.85 -0.91 -0.68 -0.48 -0.34 -0.50 -0.66 -0.65 -0.59 -0.49 -0.33
Leverage Ratio		 1.61 1.47 1.47 1.20 1.13 1.15 1.05 1.01 1.06 1.13 1.14
Compound Leverage Factor		 -7.86 1.63 1.65 1.46 1.13 0.58 1.06 0.00 1.06 1.13 1.14
Debt to Total Capital		 0.00% 19.19% 16.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 19.19% 16.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.01% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 80.79% 83.69% 99.97% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.72 -0.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.46 1.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.88 -0.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.01 1.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.95 1.32 3.10 13.50 -7.78 9.62 85.78 23.85 -8.02 -8.03 -16.77
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.02% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 52.73 3.62 3.28 8.30 0.99 6.49 59.30 34.92 15.81 3.66 1.28
Quick Ratio		 52.37 3.58 3.24 8.03 0.90 6.36 58.43 34.07 15.25 3.53 1.19
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2.22 -10 -12 -7.76 -3.52 -11 -7.47 -5.30 -3.96 -5.91 -6.01
Operating Cash Flow to CapEx		 -91.90% 0.00% 0.00% 0.00% 0.00% 0.00% -3,440.13% -1,816.34% -3,737.38% -4,033.92% -14,884.28%
Free Cash Flow to Firm to Interest Expense		 0.84 -9.83 -10.36 -5.06 0.00 -119.56 -87.42 -1,034.69 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -2.34 -6.55 -7.09 -5.07 0.00 -71.16 -96.18 -1,149.96 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.90 -6.55 -7.09 -4.91 0.00 -71.07 -98.97 -1,213.27 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.48 4.53 9.35 11 8.05 8.05 9.39 9.02 6.72 6.67 5.96
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.16 4.04 4.82 1.24 -2.54 0.00 1.35 -0.38 -2.30 -0.05 -0.71
Enterprise Value (EV)		 67 74 74 23 16 54 33 7.66 5.27 16 21
Market Capitalization		 99 93 85 30 18 68 53 22 13 20 23
Book Value per Share		 $0.56 $0.40 $0.32 $0.26 $0.14 $2.40 $2.60 $2.00 $1.27 $0.97 $0.47
Tangible Book Value per Share		 $0.55 $0.39 $0.32 $0.25 $0.13 $2.36 $2.57 $1.97 $1.25 $0.94 $0.45
Total Capital		 32 29 24 18 11 22 30 23 15 11 7.52
Total Debt		 0.00 5.47 3.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -31 -19 -11 -7.08 -2.56 -14 -21 -14 -8.15 -4.80 -1.56
Capital Expenditures (CapEx)		 6.76 0.00 0.00 -0.24 -0.07 -0.01 0.24 0.32 0.15 0.16 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.39 -1.05 -0.52 -0.64 -2.58 -1.88 -0.04 -0.06 -0.24 -1.19 -1.19
Debt-free Net Working Capital (DFNWC)		 31 23 15 6.44 -0.02 12 20 14 7.91 3.61 0.36
Net Working Capital (NWC)		 31 18 11 6.44 -0.02 12 20 14 7.91 3.61 0.36
Net Nonoperating Expense (NNE)		 -2.75 4.52 3.58 2.04 2.36 2.25 2.70 2.43 2.33 2.33 2.75
Net Nonoperating Obligations (NNO)		 -31 -19 -11 -7.08 -2.56 -14 -21 -14 -8.15 -4.80 -1.56
Total Depreciation and Amortization (D&A)		 1.48 2.09 2.01 1.04 0.70 0.72 0.72 0.72 0.75 0.76 0.74
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.80) ($3.80) ($3.40) ($2.60) ($2.40) ($2.39) ($0.81) ($0.70) ($0.74) ($0.70) ($0.63)
Adjusted Weighted Average Basic Shares Outstanding		 2.83M 2.88M 3.01M 3.25M 3.84M 0.00 10.90M 11.53M 11.63M 11.87M 15.12M
Adjusted Diluted Earnings per Share		 ($1.80) ($3.80) ($3.40) ($2.60) ($2.40) ($2.39) ($0.81) ($0.70) ($0.74) ($0.70) ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding		 2.96M 2.88M 3.01M 3.25M 3.84M 0.00 10.90M 11.53M 11.63M 11.87M 15.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($2.40) ($2.39) ($0.81) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.86M 2.91M 3.17M 162.30K 3.59M 5.62M 10.90M 0.00 0.00 14.68M 17.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.94 -6.20 -6.72 -6.53 -6.06 -11 -6.12 -5.68 -6.26 -5.96 -6.71
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.17 -9.29 -8.26 -4.58 0.00 -284.76 -102.27 -1,581.44 0.00 0.00 0.00
NOPAT to Interest Expense		 -1.87 -5.95 -6.04 -4.26 0.00 -119.52 -71.67 -1,108.63 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2.38 -9.29 -8.26 -4.43 0.00 -284.67 -105.07 -1,644.76 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -4.42 -5.95 -6.04 -4.10 0.00 -119.42 -74.46 -1,171.94 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for NanoViricides

This table displays calculated financial ratios and metrics derived from NanoViricides' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 11,666,000.00 11,746,000.00 11,779,000.00 11,814,000.00 14,677,000.00 14,347,000.00 15,641,000.00 16,072,000.00 17,431,000.00 - 21,595,000.00
DEI Adjusted Shares Outstanding		 11,666,000.00 11,746,000.00 11,779,000.00 11,814,000.00 14,677,000.00 14,347,000.00 15,641,000.00 16,072,000.00 17,431,000.00 - 21,595,000.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.17 -0.18 -0.16 -0.20 -0.21 -0.14 -0.14 -0.13 -0.10 - -0.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -25.73% -22.73% -9.91% 35.96% -68.16% 4.23% -21.69% 10.65% 43.63% -13.99% 8.19%
EBIT Growth		 -23.09% -20.43% -8.91% 34.01% -61.82% 3.53% -19.54% 11.04% 42.91% -9.54% 10.26%
NOPAT Growth		 -25.22% -19.13% -5.39% 34.95% -55.93% 5.75% -17.86% 11.53% 43.28% -8.46% 9.73%
Net Income Growth		 -25.35% -21.19% -8.91% 34.01% -58.82% 4.13% -19.54% 11.04% 42.91% -9.53% 10.26%
EPS Growth		 -21.43% -20.00% -6.67% 36.67% -35.29% 22.22% 12.50% 36.84% 56.52% 21.43% 35.71%
Operating Cash Flow Growth		 -13.44% -22.74% -11.82% 1.15% -121.46% -27.46% -2.44% -14.89% 38.58% 6.45% 3.03%
Free Cash Flow Firm Growth		 0.00% 96.77% 76.76% 0.00% -249.37% -112.13% -207.31% 52.38% -10.92% -58.99% -127.62%
Invested Capital Growth		 -13.27% -14.44% -13.79% -0.74% -16.77% -10.79% -14.93% -10.61% -3.08% -7.89% -5.57%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 48.45% -9.70% 12.96% -30.09% -35.37% 37.52% -10.60% 4.48% 14.60% -26.35% 10.92%
EBIT Q/Q Growth		 45.88% -8.77% 11.76% -27.04% -32.72% 35.16% -9.34% 5.45% 14.83% -24.41% 10.42%
NOPAT Q/Q Growth		 44.74% -7.54% 12.65% -25.31% -32.47% 35.00% -9.23% 5.94% 15.07% -24.29% 9.09%
Net Income Q/Q Growth		 44.85% -7.43% 12.32% -27.04% -32.72% 35.16% -9.34% 5.45% 14.83% -24.41% 10.42%
EPS Q/Q Growth		 43.33% -5.88% 11.11% -18.75% -21.05% 39.13% 0.00% 14.29% 16.67% -10.00% 18.18%
Operating Cash Flow Q/Q Growth		 21.81% -46.71% -13.06% 23.78% -75.17% 15.57% 9.13% 14.52% 6.35% -28.60% 5.81%
Free Cash Flow Firm Q/Q Growth		 0.00% -13.90% 51.09% -960.92% 40.88% 30.84% 29.15% -64.41% -37.68% 0.88% -1.44%
Invested Capital Q/Q Growth		 11.66% -3.91% 2.62% -9.85% -6.37% 3.00% -2.15% -5.27% 1.51% -2.11% 0.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 0.00% 100.63% 100.00% 54.94% 100.00% 100.00% 100.00% 40.13% 100.00% 100.00% 100.00%
Interest Burden Percent		 0.00% 100.00% 100.00% 182.01% 100.00% 100.01% 100.00% 249.19% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.05% -57.90% -65.85% -63.00% -81.92% -82.01% -99.84% -99.75% -94.03% -77.53% -89.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -88.35% -80.05% -86.42% -84.81% -95.16% -90.51% -86.95% -87.86%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -52.05% -57.90% -65.85% -63.00% -81.92% -82.01% -99.84% -99.75% -94.03% -77.53% -89.97%
Return on Equity Simple (ROE_SIMPLE)		 -69.30% -75.15% -89.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.42 -1.53 -1.34 -1.67 -2.22 -1.44 -1.57 -1.48 -1.26 -1.56 -1.42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.95% -7.02% -8.04% -10.54% -19.48% -12.74% -22.15% -19.35% -21.13% -14.44% -19.74%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.28% -12.54% -14.60% -21.94% -13.88% -17.82% -19.70% -17.53% -14.12% -15.53%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.93 -2.10 -1.85 -2.36 -3.13 -2.03 -2.22 -2.10 -1.79 -2.22 -1.99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.74 -1.91 -1.66 -2.17 -2.93 -1.83 -2.03 -1.93 -1.65 -2.09 -1.86
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.21 0.96 1.28 1.77 2.18 1.98 2.07 2.99 3.47 1.84 2.15
Price to Tangible Book Value (P/TBV)		 1.24 0.99 1.32 1.82 2.25 2.04 2.15 3.12 3.63 1.89 2.23
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.36 0.93 1.41 2.33 2.91 2.58 2.51 3.51 3.93 2.56 2.77
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.53 -0.52 -0.45 -0.49 -0.40 -0.40 -0.30 -0.33 -0.29 -0.42 -0.32
Leverage Ratio		 1.09 1.04 1.04 1.13 1.18 1.09 1.10 1.14 1.16 1.11 1.13
Compound Leverage Factor		 0.00 1.04 1.04 2.05 1.18 1.09 1.10 2.84 1.16 1.11 1.13
Debt to Total Capital		 10.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 10.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 89.63% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -8.18 -6.69 -6.90 -6.51 -9.53 -7.37 -11.87 -14.02 -13.28 -7.44 -10.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.53 5.59 4.32 3.66 2.48 3.44 2.27 1.28 1.06 4.43 3.17
Quick Ratio		 7.35 5.52 4.00 3.53 2.37 3.34 2.12 1.19 0.95 4.31 3.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.27 -0.31 -0.15 -1.62 -0.96 -0.66 -0.47 -0.77 -1.07 -1.06 -1.07
Operating Cash Flow to CapEx		 -14,132.12% -31,402.54% -4,354.50% -1,509.06% -5,548.85% 0.00% 0.00% -16,685.35% -1,890.31% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -7.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -32.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -32.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 7.50 7.21 7.39 6.67 6.24 6.43 6.29 5.96 6.05 5.92 5.94
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.15 -1.22 -1.18 -0.05 -1.26 -0.78 -1.10 -0.71 -0.19 -0.51 -0.35
Enterprise Value (EV)		 10 6.74 10 16 18 17 16 21 24 15 16
Market Capitalization		 16 12 14 20 22 21 18 23 25 20 20
Book Value per Share		 $1.11 $1.06 $0.90 $0.97 $0.69 $0.72 $0.56 $0.47 $0.41 $0.62 $0.42
Tangible Book Value per Share		 $1.08 $1.03 $0.88 $0.94 $0.67 $0.70 $0.54 $0.45 $0.39 $0.60 $0.41
Total Capital		 14 12 11 11 10 10 8.83 7.52 7.17 11 9.15
Total Debt		 1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -5.47 -5.25 -3.26 -4.80 -3.87 -3.96 -2.54 -1.56 -1.13 -5.15 -3.21
Capital Expenditures (CapEx)		 0.01 0.01 0.04 0.10 0.05 0.00 0.00 0.01 0.08 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.78 -0.88 -0.55 -1.19 -1.46 -1.07 -1.01 -1.19 -1.06 -1.05 -0.90
Debt-free Net Working Capital (DFNWC)		 6.19 4.37 2.70 3.61 2.41 2.89 1.53 0.36 0.07 4.10 2.31
Net Working Capital (NWC)		 6.19 4.37 2.70 3.61 2.41 2.89 1.53 0.36 0.07 4.10 2.31
Net Nonoperating Expense (NNE)		 0.55 0.59 0.52 0.68 0.91 0.59 0.64 0.61 0.53 0.66 0.57
Net Nonoperating Obligations (NNO)		 -5.47 -5.25 -3.26 -4.80 -3.87 -3.96 -2.54 -1.56 -1.13 -5.15 -3.21
Total Depreciation and Amortization (D&A)		 0.19 0.19 0.19 0.19 0.20 0.20 0.19 0.16 0.13 0.13 0.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.18) ($0.16) ($0.19) ($0.23) ($0.14) ($0.14) ($0.12) ($0.10) ($0.11) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 11.72M 11.75M 11.78M 11.87M 13.72M 14.57M 16.03M 15.12M 17.08M 19.85M 21.61M
Adjusted Diluted Earnings per Share		 ($0.17) ($0.18) ($0.16) ($0.19) ($0.23) ($0.14) ($0.14) ($0.12) ($0.10) ($0.11) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 11.72M 11.75M 11.78M 11.87M 13.72M 14.57M 16.03M 15.12M 17.08M 19.85M 21.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.75M 11.78M 11.81M 14.68M 14.35M 15.64M 16.07M 17.43M 18.00M 21.60M 21.65M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.42 -1.53 -1.34 -1.67 -2.22 -1.44 -1.57 -1.48 -1.26 -1.56 -1.42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -52.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -38.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -53.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -39.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

NanoViricides Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NanoViricides' financial year ends in June. Their financial year 2025 ended on June 30, 2025.

NanoViricides' net income appears to be on an upward trend, with a most recent value of -$9.47 million in 2025, rising from -$2.20 million in 2015. The previous period was -$8.29 million in 2024. See NanoViricides' forecast for analyst expectations on what's next for the company.

NanoViricides' total operating income in 2025 was -$9.59 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $9.59 million

Over the last 10 years, NanoViricides' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

NanoViricides' total liabilities were at $1.31 million at the end of 2025, a 3.8% decrease from 2024, and a 89.5% decrease since 2015.

In the past 10 years, NanoViricides' cash and equivalents has ranged from $1.56 million in 2025 to $31.47 million in 2015, and is currently $1.56 million as of their latest financial filing in 2025.

Over the last 10 years, NanoViricides' book value per share changed from 0.56 in 2015 to 0.47 in 2025, a change of -15.9%.


Related Companies

Financial statements for NYSE:NNVC last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel